Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
62756-0452-36 62756-0452 Octreotide acetate BYNFEZIA Pen 2.5 mg/mL Hormonal Therapy Somatostatin Analog Subcutaneous April 29, 2020 In Use
62756-0452-37 62756-0452 Octreotide acetate BYNFEZIA Pen 2.5 mg/mL Hormonal Therapy Somatostatin Analog Subcutaneous April 29, 2020 In Use
67457-0239-00 67457-0239 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 12, 2013 In Use
67457-0239-01 67457-0239 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 1, 2011 In Use
76135-0005-01 76135-0005 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous Jan. 1, 2019 In Use
76135-0006-01 76135-0006 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous Jan. 1, 2019 In Use
76135-0009-01 76135-0009 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 1, 2019 In Use
76135-0010-01 76135-0010 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 1, 2019 In Use
76135-0011-01 76135-0011 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb. 1, 2019 In Use
67457-0245-00 67457-0245 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 12, 2013 In Use
67457-0245-01 67457-0245 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 1, 2011 In Use
67457-0246-00 67457-0246 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 12, 2013 In Use
67457-0246-01 67457-0246 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 1, 2011 In Use
00409-4229-01 00409-4229 Zoledronic Acid Zoledronic Acid 4.0 mg/100mL Ancillary Therapy Bisphosphonate Intravenous Oct. 19, 2017 July 30, 2021 In Use
42023-0151-01 42023-0151 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous March 4, 2013 Feb. 25, 2020 In Use
63323-0961-98 63323-0961 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Sept. 4, 2014 In Use
00143-2422-01 00143-2422 Ondansetron Hydrochloride Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2008 Dec. 31, 2014 In Use
00143-2422-25 00143-2422 Ondansetron Hydrochloride Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2008 Dec. 31, 2014 In Use
00143-2422-30 00143-2422 Ondansetron Hydrochloride Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2008 Dec. 31, 2014 In Use
00143-2423-01 00143-2423 Ondansetron Hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2008 Dec. 31, 2014 In Use
00143-2423-25 00143-2423 Ondansetron Hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2008 Dec. 31, 2014 In Use
00143-2423-30 00143-2423 Ondansetron Hydrochloride Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2008 Dec. 31, 2014 In Use
00143-2424-07 00143-2424 Ondansetron Ondansetron 24.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2008 Dec. 31, 2014 In Use
00143-9771-06 00143-9771 Ondansetron Hydrochloride and Dextrose Ondansetron Hydrochloride and Dextrose 32.0 mg/50mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Aug. 4, 2009 In Use
00409-1120-11 00409-1120 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Sept. 5, 2013 In Use

Found 10,000 results in 6 milliseconds — Export these results